Decoy Therapeutics (NASDAQ:DCOY) Announces Quarterly Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) posted its quarterly earnings results on Tuesday. The company reported $43.10 EPS for the quarter, FiscalAI reports.

Decoy Therapeutics Trading Up 2.0%

Decoy Therapeutics stock traded up $0.13 during trading hours on Wednesday, hitting $6.66. The company had a trading volume of 1,311 shares, compared to its average volume of 187,495. The business’s 50-day moving average is $8.29. The stock has a market capitalization of $3.53 million, a price-to-earnings ratio of -0.02 and a beta of 0.30. Decoy Therapeutics has a one year low of $5.94 and a one year high of $415.80.

Analyst Ratings Changes

Several analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on Decoy Therapeutics in a research note on Friday, January 23rd. They issued a “buy” rating and a $30.00 price objective on the stock. Weiss Ratings assumed coverage on Decoy Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Finally, Wall Street Zen upgraded Decoy Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $30.00.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.